Last reviewed · How we verify
TEZ/IVA
TEZ/IVA is a combination of tezacaftor and ivacaftor, which work together to increase the function of the CFTR protein in the lungs.
TEZ/IVA is a combination of tezacaftor and ivacaftor, which work together to increase the function of the CFTR protein in the lungs. Used for Cystic fibrosis in patients with one or two F508del mutations.
At a glance
| Generic name | TEZ/IVA |
|---|---|
| Also known as | VX-661/VX-770, tezacaftor/ivacaftor, tezacaftor/ivacaftor fixed dose combination, Tezacaftor/Ivacaftor |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Drug class | CFTR modulator |
| Target | CFTR |
| Modality | Small molecule |
| Therapeutic area | Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Tezacaftor is a corrector that helps to restore the function of the CFTR protein, while ivacaftor is a potentiator that helps to increase the amount of chloride ions that are released from the CFTR protein, leading to improved lung function in people with cystic fibrosis.
Approved indications
- Cystic fibrosis in patients with one or two F508del mutations
Common side effects
- Upper respiratory tract infection
- Nausea
- Headache
Key clinical trials
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (PHASE1)
- Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants (PHASE1)
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older (PHASE3)
- Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older (PHASE3)
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del (PHASE3)
- Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age (PHASE3)
- Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age (PHASE3)
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEZ/IVA CI brief — competitive landscape report
- TEZ/IVA updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI